Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial

DiscussionThis is the first randomised control trial to study the efficacy of rituximab as first-line treatment in CTD-associated ILD. The results generated should provide important information on the treatment of a life-threatening complication affecting a rare group of CTDs.Trial registrationClinicalTrials.gov, NCT01862926. Registered on 22 May 2013.

http://link.springer.com/10.1186/s13063-017-2016-2

Source: Trials - June 15, 2017 Category: Research Source Type: clinical trials